Clinical Trials Browser

Phase 1/2 × CA-4948 × Dermatologic × Clear all

NCT05669352 2025-04-04

A Study of Oral IRAK-4 Inhibitor CA-4948 in Combination With Pembrolizumab and Stereotactic Radiosurgery in Patients With Melanoma Brain Metastases

Phase 1/2 Suspended

CNSDermatologic

Brain Neoplasms, Melanoma